登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C26H35N5O6
化学文摘社编号:
分子量:
513.59
UNSPSC Code:
12352209
PubChem Substance ID:
NACRES:
NA.32
MDL number:
产品名称
[D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin acetate salt, ≥97% (HPLC)
SMILES string
CC(O)=O.C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc2ccccc2)C(=O)NCCO
InChI key
XZZYKCKUDLGXJA-NJUGUJQKSA-N
InChI
1S/C26H35N5O6.C2H4O2/c1-17(30-25(36)21(27)14-19-8-10-20(33)11-9-19)24(35)29-16-23(34)31(2)22(26(37)28-12-13-32)15-18-6-4-3-5-7-18;1-2(3)4/h3-11,17,21-22,32-33H,12-16,27H2,1-2H3,(H,28,37)(H,29,35)(H,30,36);1H3,(H,3,4)/t17-,21+,22+;/m1./s1
assay
≥97% (HPLC)
storage temp.
−20°C
Quality Level
Gene Information
human ... OPRM1(4988)
mouse ... OPRM1(18390)
rat ... OPRM1(25601)
正在寻找类似产品? 访问 产品对比指南
Application
[D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin acetate salt or DAMGO has been used:
- for use as a positive control in the assay of G-protein activation with μ-opioid receptor, to assay the inhibition of cAMP inhibition by DAMGO
- for the determination of the suppression of contraction by opioid receptors
- to determine whether the peripheral application of DAMGO suppresses the hypertonic saline (HS)-induced masseter nociception in slightly anaesthetized rats
Biochem/physiol Actions
Enkephalin analog that is a selective agonist at μ-opioid receptors.
General description
[D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin acetate salt or DAMGO is a full agonist of the μ-opioid receptor. μ-opioid receptor is encoded by the OPRM1 gene, which has a predominant expression in reward-processing areas of brain. It acts as a receptor for endogenous opioids such as β-endorphin, encephalin, as well as foreign opioids such as morphine, heroin, and methadone.
Packaging
Bottomless glass bottle. Contents are inside inserted fused cone.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
涉药品监管产品
此项目有
Ken W K Lee et al.
Journal of psychiatry & neuroscience : JPN, 40(1), 38-45 (2014-10-01)
Preference for fatty foods is a risk factor for obesity. It is a complex behaviour that involves the brain reward system and is regulated by genetic and environmental factors, such as the opioid receptor mu-1 gene (OPRM1) and prenatal exposure
Raza Qazi et al.
Nature biomedical engineering, 3(8), 655-669 (2019-08-07)
Both in vivo neuropharmacology and optogenetic stimulation can be used to decode neural circuitry, and can provide therapeutic strategies for brain disorders. However, current neuronal interfaces hinder long-term studies in awake and freely behaving animals, as they are limited in
Javier Llorente et al.
The European journal of neuroscience, 36(12), 3636-3642 (2012-09-26)
There is considerable controversy over whether μ-opioid receptor (MOPr) desensitization is homologous or heterologous and over the mechanisms underlying such desensitization. In different cell types MOPr desensitization has been reported to involve receptor phosphorylation by various kinases, including G-protein-coupled receptor
Frank J Meye et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 32(46), 16120-16128 (2012-11-16)
μ-Opioid receptors (MORs) in the ventral tegmental area (VTA) are pivotally involved in addictive behavior. While MORs are typically activated by opioids, they can also become constitutively active in the absence of any agonist. In the current study, we present
Jami L Saloman et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 36(42), 10769-10781 (2016-11-01)
Designer receptors exclusively activated by designer drugs (DREADDs) are an advanced experimental tool that could potentially provide a novel approach to pain management. In particular, expression of an inhibitory (Gi-coupled) DREADD in nociceptors might enable ligand-dependent analgesia. To test this
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持